Avexegen Therapeutics

Avexegen Therapeutics is a biotechnology company developing therapies for patients with gastrointestinal disorders. Its drug candidate, Neuregulin-4 (NRG-4), aims to heal damaged and inflamed gut tissue in patients with Crohn’s disease and ulcerative colitis and in premature infants with necrotizing enterocolitis.